Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in moderately to severely active Crohn's disease
ISRCTN15911581Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in Crohn's disease (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical response at Week 12, Clinical remission at Week 12 and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN15911581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15911581.